Nuo Therapeutics Financials

AURX

Trailing 12 months to June 30, 2026

Revenue $5.2M +166.6% YoY

Net Income -$2.0M +18.5% YoY

EPS (Diluted) Not reported for the trailing 12 months

Free Cash Flow -$2.4M -123.2% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Nuo Therapeutics (AURX) reported $5.2M in revenue over the twelve months to Jun 30, 2026, up 166.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AURX FY2025 2026-08-29

Revenue expansion is being absorbed by operating costs, while financing supports a cash-consuming business with a shrinking equity base.

Revenue more than doubled from $1.4M in FY2024 to $3.3M in FY2025, but the extra volume did not translate into operating profitability. Gross margin fell from 77.8% to 66.9% while SG&A reached $4.7M, indicating that cost growth and weaker gross economics absorbed much of the commercial expansion.

Net loss was -$2.5M in FY2025 while operating cash flow was -$865K, so the cash burden was materially lower than the accounting loss. That gap points to noncash expense effects and working-capital timing; receivables reached $562K, tying more funds to reported sales.

Liabilities exceeded assets in FY2025, leaving total equity at -$957K versus $514K a year earlier; the balance sheet is therefore financed more by obligations than book capital. The current ratio fell from 1.5x to 1.1x, while financing cash flow supplied $1.4M; reported cash and investments equaled 7.6 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

Nuo Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-17.21

Nuo Therapeutics scores -17.21, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($55.2M) relative to total liabilities ($2.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Nuo Therapeutics passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Nuo Therapeutics reported a net loss of $2.5M while operations used $865K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.3M

YoY+142.7%

10Y CAGR-8.2%

Nuo Therapeutics generated $3.3M in revenue in fiscal year 2025. This represents an increase of 142.7% from the prior year.

EBITDA

-$2.4M

YoY+0.1%

Nuo Therapeutics's EBITDA was -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.1% from the prior year.

Net Income

-$2.5M

YoY-8.1%

Nuo Therapeutics reported -$2.5M in net income in fiscal year 2025. This represents a decrease of 8.1% from the prior year.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$1.1M

YoY+52.2%

Nuo Therapeutics recorded an outflow of $1.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 52.2% from the prior year.

Cash & Debt

$549K

YoY+93.5%

5Y CAGR+27.7%

10Y CAGR-28.6%

Nuo Therapeutics held $549K in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

48M

YoY+3.1%

5Y CAGR+9.8%

10Y CAGR-9.1%

Nuo Therapeutics had 48M shares outstanding in fiscal year 2025. This represents an increase of 3.1% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

66.9%

YoY-10.9pp

Nuo Therapeutics's gross margin was 66.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 10.9 percentage points from the prior year.

Operating Margin

-75.9%

Nuo Therapeutics's operating margin was -75.9% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

-75.8%

Nuo Therapeutics's net profit margin was -75.8% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

Capital Expenditures

$275K

YoY+77.3%

Nuo Therapeutics invested $275K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 77.3% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

Share Buybacks

Not reported for fiscal year 2025.

AURX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AURX quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY15	FY14	FY13	FY12	FY11	FY10
Revenue	$5.2M	$3.3M+142.7%	$1.4M+124.3%	$609K+442.1%	$112K	$0	$0-100.0%	$146K-89.3%	$1.4M+90.1%	$721K	$11.5M+48.3%	$7.8M-32.9%	$11.6M+9.5%	$10.6M+45.8%	$7.2M+85.3%	$3.9M
Cost of Revenue	$1.9M	$1.1M+261.8%	$303K+140.2%	$126K+556.3%	$19K	$0	$0-100.0%	$115K-29.7%	$163K-85.1%	$1.1M	$8.0M+17.7%	$6.8M-19.9%	$8.5M+115.9%	$3.9M+43.5%	$2.7M+69.1%	$1.6M
Gross Profit	$3.3M	$2.2M+108.8%	$1.1M+120.2%	$482K+418.5%	$93K	$0	$0-100.0%	$32K-97.4%	$1.2M+426.4%	-$370K	$3.5M+257.5%	$991K-68.2%	$3.1M-53.1%	$6.6M+47.1%	$4.5M+96.7%	$2.3M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$181K-68.6%	$576K-56.6%	$1.3M	$2.6M-36.8%	$4.0M+6.3%	$3.8M+12.2%	$3.4M+3350.3%	$98K-76.4%	$416K
SG&A Expenses	$5.1M	$4.7M+34.5%	$3.5M-3.6%	$3.7M+6.9%	$3.4M+3664.9%	$91K-76.0%	$378K-52.1%	$789K-61.0%	$2.0M-47.1%	$3.8M	$9.0M-8.7%	$9.9M+45.6%	$6.8M+21.6%	$5.6M+89.4%	$2.9M+11.9%	$2.6M
Operating Income	-$1.7M	-$2.5M-2.4%	-$2.5M+22.4%	-$3.2M+4.6%	-$3.3M-3562.3%	-$91K+76.0%	-$378K+61.0%	-$969K+35.6%	-$1.5M	N/A	-$41.3M-76.6%	-$23.4M-29.3%	-$18.1M-40.3%	-$12.9M-266.9%	-$3.5M+35.0%	-$5.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$48K-78.1%	$221K+469.5%	$39K+260.1%	$11K	$39.3M+2209.0%	$1.7M	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	-$89K-554.5%	$20K+5.4%	$19K+3.3%	$18K0.0%	$18K+28.6%	$14K
Net Income	-$2.0M	-$2.5M-8.1%	-$2.3M+26.7%	-$3.2M0.0%	-$3.2M-3398.1%	-$91K+0.2%	-$91K+92.4%	-$1.2M+22.5%	-$1.5M	N/A	-$52.8M-179.7%	-$18.9M+6.7%	-$20.2M-2.3%	-$19.8M-464.0%	-$3.5M+48.5%	-$6.8M
EPS (Diluted)	—	N/A	N/A	N/A	N/A	-$0.03-111.1%	$0.27+640.0%	-$0.05+28.6%	-$0.07+93.1%	-$1.02	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$1.8M+35.9%	$1.3M+18.7%	$1.1M+6.3%	$1.0M+47.4%	$700K+44.6%	$484K+22.7%	$395K+6.4%	$371K
Cost of Revenue	$599K+32.4%	$452K+10.8%	$408K+0.4%	$407K+155.2%	$159K+31.7%	$121K+40.1%	$86K-14.0%	$101K
Gross Profit	$1.2M+37.7%	$850K+23.4%	$688K+10.1%	$625K+15.6%	$541K+48.8%	$363K+17.8%	$308K+14.1%	$270K
SG&A Expenses	$1.3M+3.1%	$1.3M+2.2%	$1.3M+8.8%	$1.2M-2.3%	$1.2M+7.6%	$1.1M+18.2%	$938K+10.6%	$848K
Operating Income	-$167K+62.7%	-$446K+22.9%	-$579K-7.3%	-$540K+17.2%	-$652K+12.5%	-$745K-18.4%	-$629K-9.0%	-$577K
Net Income	-$278K+55.1%	-$618K-6.9%	-$578K-7.5%	-$538K+17.2%	-$650K+12.9%	-$746K-50.2%	-$497K+14.1%	-$578K

Not reported in any period shown, so not listed: R&D Expenses, Interest Expense, Income Tax, EPS (Diluted).

AURX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AURX quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY15	FY14	FY13	FY12	FY11	FY10
Total Assets	$1.8M+55.2%	$1.2M-36.7%	$1.9M-38.4%	$3.0M+107.9%	$1.5M+808.1%	$161K-41.6%	$277K-71.7%	$975K-31.5%	$1.4M	$7.1M-87.4%	$56.2M+21.6%	$46.3M+4.3%	$44.3M+339.9%	$10.1M+13.2%	$8.9M
Current Assets	$1.4M+64.0%	$842K-46.2%	$1.6M-40.7%	$2.6M+79.7%	$1.5M+808.1%	$161K-41.6%	$277K-68.1%	$867K-26.9%	$1.2M	$3.0M-85.8%	$21.4M+115.0%	$10.0M+54.4%	$6.4M+24.9%	$5.2M+47.6%	$3.5M
Cash & Equivalents	$549K+93.5%	$284K-69.4%	$929K-54.7%	$2.1M+45.0%	$1.4M+776.3%	$161K+697.1%	$20K-96.8%	$637K-8.2%	$694K	$922K-94.2%	$15.9M+385.2%	$3.3M+25.6%	$2.6M+16.5%	$2.2M+251.6%	$639K
Inventory	$214K+42.1%	$150K-28.2%	$210K-12.7%	$240K	$0	N/A	N/A	$25K-28.8%	$36K	$254K-54.3%	$557K-49.9%	$1.1M-5.0%	$1.2M+113.5%	$548K-12.7%	$628K
Accounts Receivable	$562K+126.3%	$248K-1.0%	$251K+171.6%	$92K	$0	$0	$0	N/A	N/A	N/A	N/A	$3.9M	N/A	N/A	$1.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$1.1M0.0%	$1.1M+59.7%	$707K0.0%	$707K
Total Liabilities	$2.8M+314.7%	$676K-19.4%	$839K-2.0%	$856K+27.2%	$673K+1.2%	$665K-55.2%	$1.5M+40.5%	$1.1M+12.4%	$941K	$43.1M+7.1%	$40.3M+107.1%	$19.4M+207.2%	$6.3M-6.9%	$6.8M-24.3%	$9.0M
Current Liabilities	$1.3M+125.8%	$578K-14.2%	$675K+12.3%	$600K-10.8%	$673K+1.2%	$665K-55.2%	$1.5M+40.5%	$1.1M+12.9%	$937K	$42.2M+396.4%	$8.5M-19.5%	$10.6M+275.5%	$2.8M-10.4%	$3.1M-39.3%	$5.2M
Long-Term Debt	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$957K-286.2%	$514K-50.6%	$1.0M-52.6%	$2.2M+176.4%	$793K+257.5%	-$504K+58.4%	-$1.2M-1374.8%	-$82K-117.0%	$483K	-$36.6M-336.4%	$15.5M-41.2%	$26.3M-30.8%	$38.0M+1058.1%	$3.3M+4240.7%	-$79K
Retained Earnings	-$34.8M-7.8%	-$32.3M-7.8%	-$29.9M-11.8%	-$26.8M-13.4%	-$23.6M-0.4%	-$23.5M-0.4%	-$23.4M-5.4%	-$22.2M-7.5%	-$20.7M	-$162.9M-48.0%	-$110.1M-20.7%	-$91.2M-28.5%	-$71.0M-38.7%	-$51.2M-7.4%	-$47.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$2.6M+35.0%	$1.9M+5.4%	$1.8M-4.3%	$1.9M+41.8%	$1.4M+18.6%	$1.1M-3.6%	$1.2M-30.8%	$1.7M
Current Assets	$2.0M+31.1%	$1.5M+10.2%	$1.4M-5.7%	$1.5M+71.4%	$853K+41.9%	$602K-28.5%	$842K-37.3%	$1.3M
Cash & Equivalents	$449K+70.3%	$264K-51.9%	$549K+6.6%	$515K+62.7%	$316K+468.4%	$56K-80.4%	$284K-58.5%	$684K
Inventory	$270K+8.4%	$249K+16.3%	$214K+6.0%	$202K+21.6%	$166K+67.2%	$99K-34.1%	$150K-10.3%	$168K
Accounts Receivable	$1.2M+33.6%	$874K+55.5%	$562K-13.9%	$652K+103.5%	$320K+15.9%	$277K+11.4%	$248K-24.6%	$329K
Total Liabilities	$4.2M+25.0%	$3.3M+18.8%	$2.8M+19.4%	$2.3M+7.5%	$2.2M+60.6%	$1.4M+101.2%	$676K-18.5%	$829K
Current Liabilities	$1.6M+13.5%	$1.4M+4.8%	$1.3M+4.0%	$1.3M+25.8%	$999K-22.0%	$1.3M+121.4%	$578K-19.0%	$714K
Total Equity	-$1.5M-10.9%	-$1.4M-44.7%	-$957K-128.0%	-$420K+49.1%	-$825K-287.0%	-$213K-141.5%	$514K-42.3%	$890K
Retained Earnings	-$35.7M-0.8%	-$35.4M-1.8%	-$34.8M-1.7%	-$34.2M-1.6%	-$33.7M-2.0%	-$33.0M-2.3%	-$32.3M-1.6%	-$31.8M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

AURX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AURX quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY15	FY14	FY13	FY12	FY11	FY10
Operating Cash Flow	-$2.1M	-$865K+61.2%	-$2.2M+29.6%	-$3.2M+14.5%	-$3.7M-2989.6%	-$120K-122.9%	-$54K+94.2%	-$922K-5.4%	-$874K+82.2%	-$4.9M	-$14.4M+17.4%	-$17.4M-52.8%	-$11.4M-0.1%	-$11.4M-168.7%	-$4.2M-19.9%	-$3.5M
Capital Expenditures	$297K	$275K+77.3%	$155K+2039.2%	$7K-87.9%	$60K	$0	$0	$0	N/A	N/A	$698K+44.6%	$483K-35.7%	$751K	N/A	$66K-91.4%	$775K
Free Cash Flow	-$2.4M	-$1.1M+52.2%	-$2.4M+24.8%	-$3.2M+15.7%	-$3.8M-3039.6%	-$120K-122.9%	-$54K+94.2%	-$922K	N/A	N/A	-$15.1M+15.7%	-$17.9M-47.4%	-$12.2M	N/A	-$4.3M+0.1%	-$4.3M
Investing Cash Flow	-$297K	-$275K-77.3%	-$155K-2039.2%	-$7K+87.9%	-$60K	$0	$0	$0-100.0%	$2K+4.5%	$2K	N/A	N/A	N/A	-$1.6M-7074.8%	$23K+100.8%	-$2.7M
Financing Cash Flow	$2.6M	$1.4M-19.3%	$1.7M-12.8%	$2.0M-55.2%	$4.5M+224.7%	$1.4M+604.1%	$195K-36.1%	$305K-62.6%	$816K-72.1%	$2.9M	N/A	N/A	N/A	$13.4M+129.3%	$5.8M+21.7%	$4.8M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$471	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$236K+69.8%	-$784K-85.6%	-$423K+40.2%	-$707K-369.3%	$262K+14276.2%	$2K+100.4%	-$491K-0.6%	-$487K
Capital Expenditures	$253K+29773.3%	$847-98.0%	$43K	$0-100.0%	$2K-99.3%	$230K	$0-100.0%	$151K
Free Cash Flow	-$490K+37.7%	-$785K-68.5%	-$466K+34.1%	-$707K-371.0%	$261K+214.3%	-$228K+53.5%	-$491K+23.2%	-$638K
Investing Cash Flow	-$253K-29773.3%	-$847+98.0%	-$43K	$0+100.0%	-$2K+99.3%	-$230K	$0+100.0%	-$151K
Financing Cash Flow	$675K+35.0%	$500K0.0%	$500K-44.7%	$905K	$0	$0-100.0%	$90K-89.4%	$849K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

AURX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

AURX quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY15	FY14	FY13	FY12	FY11	FY10
Gross Margin	66.9%-10.9pp	77.8%-1.5pp	79.3%-3.6pp	82.9%	N/A	N/A	21.6%-66.5pp	88.1%+139.4pp	-51.3%	30.8%+18.0pp	12.8%-14.2pp	27.0%-36.0pp	62.9%+0.6pp	62.4%+3.6pp	58.8%
Operating Margin	-75.9%	-180.0%	-520.6%	-2958.2%	N/A	N/A	-663.0%	-109.8%	N/A	-359.0%	-301.4%	-156.4%	-122.1%	-48.5%	-138.2%
Net Margin	-75.8%	-170.2%	-521.2%	-2825.6%	N/A	N/A	-817.4%	-112.5%	N/A	-458.8%	-243.3%	-175.0%	-187.4%	-48.4%	-174.3%
Return on Equity	N/A	-452.3%-147.1pp	-305.2%-160.5pp	-144.7%-133.3pp	-11.4%	N/A	N/A	N/A	N/A	N/A	-122.1%-45.1pp	-77.0%-24.9pp	-52.1%+54.9pp	-107.0%	N/A
Return on Assets	-136.1%+59.2pp	-195.3%-26.5pp	-168.9%-64.8pp	-104.1%-97.9pp	-6.2%+50.1pp	-56.3%+375.8pp	-432.1%-274.0pp	-158.1%	N/A	-746.5%-713.0pp	-33.6%+10.2pp	-43.8%+0.9pp	-44.7%-9.8pp	-34.8%+41.8pp	-76.6%
Current Ratio	1.06-0.4x	1.45-0.9x	2.32-2.1x	4.39+2.2x	2.18+1.9x	0.24+0.1x	0.19-0.6x	0.82-0.4x	1.26	0.07-2.4x	2.52+1.6x	0.94-1.3x	2.29+0.6x	1.64+1.0x	0.68
Debt-to-Equity	N/A	1.32+0.5x	0.81+0.4x	0.39+0.4x	0.00	N/A	N/A	N/A	1.95	N/A	2.60+1.9x	0.74+0.6x	0.17-1.9x	2.07	N/A
FCF Margin	-34.4%	-174.8%	-521.8%	-3355.1%	N/A	N/A	-630.5%	N/A	N/A	-131.1%	-230.7%	-105.0%	N/A	-59.4%	-110.2%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	66.1%+0.9pp	65.3%+2.5pp	62.8%+2.2pp	60.6%-16.6pp	77.2%+2.2pp	75.0%-3.1pp	78.1%+5.2pp	72.9%
Operating Margin	-9.4%+24.9pp	-34.3%+18.5pp	-52.8%-0.5pp	-52.3%+40.8pp	-93.1%	-153.8%	-159.3%	-155.7%
Net Margin	-15.7%+31.8pp	-47.5%+5.2pp	-52.7%-0.6pp	-52.1%+40.7pp	-92.8%	-154.0%	-125.8%	-155.9%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	-96.7%-31.8pp	-64.9%
Return on Assets	-10.6%+21.2pp	-31.8%-0.5pp	-31.3%-3.4pp	-27.9%+19.9pp	-47.8%+17.3pp	-65.1%-23.3pp	-41.8%-8.1pp	-33.6%
Current Ratio	1.28+0.2x	1.11+0.1x	1.06-0.1x	1.16+0.3x	0.85+0.4x	0.47-1.0x	1.45-0.4x	1.88
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	1.32+0.4x	0.93
FCF Margin	-27.7%+32.6pp	-60.3%-17.8pp	-42.5%+26.0pp	-68.5%-105.7pp	37.2%+84.3pp	-47.1%	-124.2%	-172.1%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$957K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Biostem Tech BSEM

$62.9M

Arch Biopartners ACHFF

$49.6M

Satellos Bioscience Inc MSCLF

$187.7M

Medicenna Therapeutics Corp MDNAF

$28.9M

Hemogenyx Pharma HOPHF

$15.8M

Where Nuo Therapeutics Ranks

Frequently Asked Questions

What is Nuo Therapeutics's annual revenue?

Nuo Therapeutics (AURX) reported $3.3M in total revenue for fiscal year 2025. This represents a 142.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Nuo Therapeutics's revenue growing?

Nuo Therapeutics (AURX) revenue grew by 142.7% year-over-year, from $1.4M to $3.3M in fiscal year 2025.

Is Nuo Therapeutics profitable?

No, Nuo Therapeutics (AURX) reported a net income of -$2.5M in fiscal year 2025, with a net profit margin of -75.8%.

What is Nuo Therapeutics's EBITDA?

Nuo Therapeutics (AURX) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Nuo Therapeutics's gross margin?

Nuo Therapeutics (AURX) had a gross margin of 66.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Nuo Therapeutics's operating margin?

Nuo Therapeutics (AURX) had an operating margin of -75.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Nuo Therapeutics's net profit margin?

Nuo Therapeutics (AURX) had a net profit margin of -75.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Nuo Therapeutics's free cash flow?

Nuo Therapeutics (AURX) recorded an outflow of $1.1M in free cash flow during fiscal year 2025. This represents a 52.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Nuo Therapeutics's operating cash flow?

Nuo Therapeutics (AURX) recorded an outflow of $865K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Nuo Therapeutics's total assets?

Nuo Therapeutics (AURX) had $1.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Nuo Therapeutics's capital expenditures?

Nuo Therapeutics (AURX) invested $275K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Nuo Therapeutics have outstanding?

Nuo Therapeutics (AURX) had 48M shares outstanding as of fiscal year 2025.

What is Nuo Therapeutics's current ratio?

Nuo Therapeutics (AURX) had a current ratio of 1.06 as of fiscal year 2025, which is considered adequate.

What is Nuo Therapeutics's return on assets (ROA)?

Nuo Therapeutics (AURX) had a return on assets of -136.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Nuo Therapeutics's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Nuo Therapeutics (AURX) held $549K in cash, cash equivalents and investments, and reported an operating cash outflow of $865K over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Nuo Therapeutics's debt-to-equity ratio negative or not reported?

Nuo Therapeutics (AURX) has negative shareholder equity of -$957K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Nuo Therapeutics's Altman Z-Score?

Nuo Therapeutics (AURX) has an Altman Z-Score of -17.21, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Nuo Therapeutics's Piotroski F-Score?

Nuo Therapeutics (AURX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nuo Therapeutics's earnings high quality?

Nuo Therapeutics (AURX) reported a net loss of $2.5M while operations used $865K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.